# Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

> **NCT07323056** · PHASE2 · RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 36 (estimated)

## Conditions studied

- EGFR-mutant Non-small Cell Lung Cancer
- Potentially Resectable

## Interventions

- **DRUG:** Sacituzumab Tirumotecan and Limertinib

## Key facts

- **NCT ID:** NCT07323056
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07323056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07323056, "Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07323056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*